Also he made a pretty positive statement here,.. if true then it could explain what the company is sharing with HL and others to continually get financing. The eGFR is low in ALL patients, both Treated and Placebo groups,.. so it would be an amazing indicator if eGFR was up,... it could ONLY mean it comes from the treated group.

Blinded data is also pointing in the right direction for the other end points – eGFR data “looks stunning, seeing amazing increases, unheard of”, cognitive improvement (MoCA test) data also encouraging (looking for >1.5 units improvement; anything <18 is considered Alzheimers).